About the Author:
Jeff Nunn is the founder of Project Biohacking. With over 30 years of biohacking practice, he applies decades of self-experimentation methodology to peptide research, dosing math, and vendor evaluation.
What Peptides Can Compounding Pharmacies Legally Sell in 2025?
Jeff Nunn • October 24, 2025
A Complete Guide to FDA Regulations, Compliance Requirements, and FDA Banned Peptide list 2025
If you’re searching “compounding pharmacy peptides,” you’re probably really asking: Is it legal? Is it FDA-approved? Is this a real pharmacy—or a “research peptide” seller?
Here’s the key truth up front:
Compounded drugs are not FDA-approved. That means FDA does not verify the safety, effectiveness, or quality of a compounded drug before it’s sold or dispensed. U.S. Food and Drug Administration
This guide explains what is allowed under U.S. compounding law, what the FDA has specifically flagged as higher-risk (including “Category 2” peptides), and how to verify whether a seller is actually operating as a legitimate compounding pharmacy.
Last updated: December 12, 2025
Quick Answers:
Are compounding pharmacy peptides legal?
- Sometimes—but only under strict rules. In the U.S., compounding is generally done under two legal frameworks:
- 503A (traditional compounding pharmacy): patient-specific prescriptions; primarily overseen day-to-day by state boards of pharmacy; exempt from FDA CGMP requirements if it meets 503A conditions. U.S. Food and Drug Administration
- 503B (outsourcing facility): can compound in larger batches for clinics/office use; primarily overseen by FDA; subject to CGMP requirements and FDA inspections. U.S. Food and Drug Administration+1
Can compounding pharmacies legally sell BPC-157?
- No! Legally compliant 503A/503B compounding pharmacies in the U.S. should not be selling BPC‑157 for patients.
- Any BPC‑157 labeled as a “compounded medication” for human use is, at best, operating against FDA guidance and may be subject to enforcement.
1. Core Legal Restrictions (503A vs 503B)
Not all compounding pharmacies operate under the same rules. The FDA distinguishes between two types of facilities, each with vastly different capabilities:
| Rule | 503A (Traditional Pharmacy) | 503B (Outsourcing Facility) |
|---|---|---|
| Patient-specific prescription required? | YES | NO (can make office stock) |
| Bulk drug substances allowed? | Only from FDA’s 503A Bulks List | From 503B Bulks List (stricter) |
| Can copy FDA-approved drugs? | NO — unless "clinically different" or during shortage | NO — unless on shortage list |
| Interstate sales limit | ≤5% of total prescriptions | Unlimited |
| CGMP required? | NO (USP <795>/<797>) | YES (full FDA GMP) |
| Adverse event reporting? | Voluntary | Mandatory |
Bottom line: You cannot legally compound a peptide if it’s:
- FDA-approved and not in shortage
- Not on the FDA Bulks List
- Marketed for general use (not patient-specific)
2. FDA Bulk Drug Substances Lists (What Peptides Are Allowed?)
The FDA maintains
three lists that determine which peptides can be used in compounding:
| List | Status | Peptides Allowed? |
|---|---|---|
| Category 1 (Approved for Compounding) | Active | Very few peptides (e.g., vasopressin, oxytocin, cosyntropin) |
| Category 2 (Under Review) | Pending | Some peptides in evaluation |
| Category 3 (NOT Allowed) | Banned | GLP-1s, GHRPs, BPC-157, TB-500, etc. |
Officially Banned or Restricted Peptides (2025)
| Peptide | Status | Reason |
|---|---|---|
| Semaglutide | BANNED post-shortage (Feb 2025) | FDA-approved (Ozempic/Wegovy); off shortage list |
| Tirzepatide | BANNED post-shortage (Oct 2024) | FDA-approved (Mounjaro/Zepbound) |
| Retatrutide, Cagrilintide | NEVER allowed | Investigational; no approval |
| BPC-157 | NOT on any bulks list | No clinical data; safety unknown |
| TB-500 (Thymosin Beta-4) | BANNED | Not on bulks list; no FDA review |
| Ipamorelin, CJC-1295, GHRP-6 | NOT allowed | Not on bulks list; no safety data |
| AOD-9604, Tesamorelin | Gray area | Not on list; some 503B tried — got warning letters |
Source: FDA Bulks List (updated Sep 2025)
3. Shortage Exception (Temporary Loophole — Now Closed)
| Drug | Shortage Period | Compounding Allowed Until |
|---|---|---|
| Tirzepatide | 2023 – Oct 2, 2024 | Dec 2024 (503A) / Jan 2025 (503B) |
| Semaglutide | 2023 – Feb 7, 2025 | Apr 2025 (503A) / May 2025 (503B) |
- After these dates: No compounding allowed — even with a prescription.
- FDA issued >150 warning letters in 2025 for continued sales.
4. Other Restrictions (Even If on Bulks List)
Even allowed peptides cannot be:
- Sold with dosing guides, before/after photos, or weight loss claims
- Marketed as "same as Ozempic" or "bioidentical"
- Shipped interstate (503A >5% rule)
- Made in non-sterile conditions (USP <797>)
Example: A pharmacy compounding vasopressin for research must:
- Have a patient-specific Rx
- Use FDA-inspected API
- Label: “For Research Use Only – Not for Human Use” (if not prescribed)
5. Enforcement Actions (2025 Examples)
| Pharmacy | Peptide | Violation | Penalty |
|---|---|---|---|
| Empower Pharma | Tirzepatide | CGMP failure, post-shortage sales | Recall + FDA inspection |
| GLP-1 Solution | Retatrutide | Unapproved new drug | Cease distribution |
| DirectMeds | Semaglutide | Misbranding (“same as Wegovy”) | Warning letter |
| Peptide Sciences (online) | BPC-157 | Sold without Rx, human use implied | Shopify shutdown + payment freeze |
FDA now uses AI to scan websites, Telegram, Discord, and Reddit for violations.
6. What Can Compounding Pharmacies Legally Sell? (2025)
| Allowed (with restrictions) | Notes |
|---|---|
| Oxytocin | For labor induction (Rx only) |
| Vasopressin | For diabetes insipidus |
| Cosyntropin | For adrenal testing |
| Custom peptide mixes | Only if all components on bulks list and patient-specific |
| Non-peptide compounds | Hormones, vitamins, etc. |
No “research peptide” loophole — selling BPC-157/TB-500 as “Not for human use” is still illegal if marketed online.
7. Workarounds Some Pharmacies Try (Risky & Often Fail)
| Tactic | Legality | Outcome |
|---|---|---|
| Use salt forms (e.g., semaglutide sodium) | Claims “not the same” | FDA says NO — still unapproved |
| Sell via telemedicine + 503A Rx | Requires real doctor visit | Many shut down |
| Use crypto/offshore payment | Avoids Stripe bans | Still violates FD&C Act |
| Label as “veterinary use” | Misbranding | FDA seizures |
8. Bottom Line: What You Need to Know
| Question | Answer |
|---|---|
| Can pharmacies compound semaglutide? | NO (as of Feb 2025) |
| Can they sell BPC-157 or TB-500? | NO — not on FDA bulks list |
| Are “research peptide” sites legal? | NO — if implying human use |
| Can 503B facilities make GLP-1s? | Only if on shortage list (currently none are) |
| Is there any legal way to get compounded peptides? | Only with Rx, from licensed 503A/B, using approved API, for allowed peptides |
The Bottom Line: For Compounding Pharmacies Compliance Isn't Optional
The peptide compounding industry is under intense FDA scrutiny, and the consequences of non-compliance are severe for compounding pharmacies ranging from warning letters and product recalls to criminal prosecution and loss of pharmacy licenses. With AI-powered monitoring scanning online marketplaces and social media, there's no flying under the radar.
For pharmacies: If you're unsure whether you can compound a specific peptide, the answer is probably no. When in doubt, consult the FDA Bulks List, seek legal counsel, and prioritize patient safety over profit margins.
For consumers: Take note! Your choices for peptides are severely limited by the FDA. The research peptide market is a gray market with caution and due diligence risks can be mitigated to a degree but it will always exist.
The regulations are clear, the enforcement is real, and the stakes are high. Stay informed, demand transparency from your suppliers, and always verify that every peptide with a 3rd party COA.
Your health depends on it.
Sources & Monitoring
Sources: FDA.gov (503A/503B Guidance, Bulks List, Warning Letters), USP <797>, DQSA 2013, Avalere Health, Pharmacy Times
Monitor: FDA Compounding Page — updated weekly
FAQ
Can I still get compounded semaglutide or tirzepatide from my pharmacy?
No. As of February 2025 for semaglutide and October 2024 for tirzepatide, these drugs are no longer in shortage and cannot legally be compounded by any pharmacy—503A or 503B. Any pharmacy still selling these compounds is violating FDA regulations and risks enforcement action. If you were using compounded versions, you'll need to transition to the FDA-approved branded medications (Ozempic, Wegovy, Mounjaro, or Zepbound) or discuss alternative treatments with your healthcare provider.
What's the difference between a 503A and 503B compounding facility?
A 503A facility is a traditional compounding pharmacy that must have a patient-specific prescription for each compound and is limited to 5% interstate sales. A 503B outsourcing facility operates under stricter FDA oversight with full current good manufacturing practice (CGMP) requirements but can produce larger batches without individual prescriptions and sell across state lines without restriction. Both must only use peptides from the FDA's approved bulks list, though their specific lists differ slightly.
My doctor prescribed a compounded peptide—does that make it legal?
Not necessarily. Even with a valid prescription, the peptide must be on the FDA's approved bulks list for compounding. A prescription doesn't override federal regulations. If your doctor prescribed a banned peptide like BPC-157 or post-shortage semaglutide, the pharmacy cannot legally fill it, and doing so puts both the pharmacy and prescriber at risk. Always verify that your prescribed peptide is on the current FDA bulks list.
How can I verify if a compounding pharmacy is legitimate?
Check for these key indicators: state pharmacy license number, National Drug Code (NDC) numbers for their compounds, membership in professional organizations like PCCA or APC, and compliance with USP standards for sterile compounding. Legitimate pharmacies will provide Certificates of Analysis (COA) with HPLC testing results, require valid prescriptions, and won't make health claims or provide dosing protocols on their websites. You can also verify their license through your state board of pharmacy.
Will the FDA ever allow compounding of popular weight loss peptides again?
Only if they return to shortage status, which is unlikely given manufacturers have scaled up production. The FDA's position is clear: compounding of FDA-approved drugs is only permitted during verified shortages. Unless semaglutide or tirzepatide face supply disruptions that result in official FDA shortage declarations, compounding will remain prohibited. Pharmacies claiming they can provide these compounds "legally" through workarounds are misrepresenting the law and should be avoided.
Is Peptide Sciences a compounding pharmacy?
According to Peptide Sciences’ own disclosures, it is a chemical supplier and is not a 503A compounding pharmacy or a 503B outsourcing facility.
What are Category 2 peptides?
They are bulk drug substances FDA has identified as having significant safety risks under its interim compounding policies, and they are not covered by the “Category 1” enforcement discretion approach.
Is Ipamorelin FDA approved?
No. FDA also lists ipamorelin acetate as Category 2 (503B interim policy).
Are compounded peptides FDA approved?
No—compounded drugs are not FDA-approved.
Is there an FDA banned peptides list?
Not as one single “banned list.” The closest equivalents for compounding are FDA’s bulk substance eligibility rules and the Category 2 safety-risk list.
Disclaimer:
This article is for informational and educational purposes only and does not constitute legal, medical, or professional advice. The information provided is based on FDA regulations and guidance documents current as of the publication date, but pharmaceutical compounding laws are subject to frequent changes and updates.
Not Legal Advice: This content should not be relied upon as legal counsel. Compounding pharmacies, healthcare providers, and businesses should consult with qualified legal professionals and regulatory experts before making compliance decisions.
Not Medical Advice: This article does not provide medical recommendations or endorse any specific treatments. Patients should consult with licensed healthcare providers regarding their individual medical needs and treatment options.
No Warranty: While we strive for accuracy, we make no representations or warranties regarding the completeness, accuracy, or timeliness of the information provided. Regulatory guidance can change without notice, and readers are responsible for verifying current regulations with the FDA and relevant state boards.
Use at Your Own Risk: The author and publisher assume no liability for actions taken based on the information in this article. Violation of FDA regulations can result in serious legal consequences including fines, criminal prosecution, and loss of professional licenses.
Always verify current FDA guidance, consult qualified legal and medical professionals, and review the most recent FDA Bulks Lists and shortage declarations before making any decisions related to peptide compounding.
Important Disclaimer: The content on Project Biohacking is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional before making any changes to your health regimen, starting new supplements, peptides, or protocols. Nothing on this site establishes a doctor–patient relationship, and you use the information at your own risk. Research compounds discussed here are sold for laboratory research purposes only and are not approved for human or veterinary use or consumption.